MediWound Ltd.
MDWD•NASDAQ•Healthcare•Biotechnology

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOOfer Gonen
Founded2000
IPO DateMarch 20, 2014
Employees111
CountryIsrael
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.mediwound.com
Phone972 7 797 14100
Address
42 Hayarkon Street Yavne, 8122745 Israel

Corporate Identifiers

CIK0001593984
CUSIPM68830104
ISINIL0011316309
SIC2833

Leadership Team & Key Executives

Ofer Gonen B.Sc.
Chief Executive Officer
Hani Luxenburg
Chief Financial Officer
Dr. Shmulik Hess Ph.D.
Chief Operating Officer and Chief Commercial Officer
Yaron Meyer Adv.
Executive Vice President, General Counsel and Corporate Secretary
Dr. Ety Klinger MBA, Ph.D.
Chief Research and Development Officer
Dr. Liron Gal
Vice President of Manufacturing Science and Technology
Barry J. Wolfenson
Executive Vice President of Strategy and Corporate Development
Hagit Mashiach
Vice President of Human Resources
Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.
Chief Medical Officer